Company news

Tarsus Pharmaceuticals, Inc. news in 2024

Tarsus Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

November 12, 2024

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

November 12, 2024

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

November 5, 2024

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

November 4, 2024

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

October 16, 2024

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

September 24, 2024

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

August 27, 2024

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

August 7, 2024

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 28, 2024

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

May 8, 2024

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

May 7, 2024

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

April 30, 2024

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

April 22, 2024

Tarsus to Participate at Upcoming Investor Conferences

March 4, 2024

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

March 4, 2024

Tarsus Announces Pricing of $100.0 Million Public Offering

February 29, 2024

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

February 26, 2024

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

February 21, 2024

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

February 19, 2024

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

January 30, 2024

Calls in 2024

Decks in 2024